FIRST TURN MANAGEMENT LLC
Q3 2024 Form 13-F
DEL MAR, DELAWARE
CIK 0001993440
· CRD 327421
· SEC-registered investment adviser
$631.6M Reported Value Total
FIRST TURN MANAGEMENT, LLC reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $599,408,142, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
2 funds
· $36.3M gross asset value
Hedge Fund: $36.3M
Source: Form ADV filed 2026-03-25
Reported value
$631.6M
Quarter over quarter
+10.1%
Holdings
38
Top-10 concentration
39.3%
Key People
Form ADV owners & control persons
Lisa Gable Wheatley
MANAGER
Tracy Austin Murphy
DIRECTOR
Catherine Revelle Newcomb
CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2024 13F record
Q3 2024 13F filing summary
| Period of report | September 30, 2024 |
|---|---|
| Filed | November 07, 2024 |
| Form | 13F-HR |
| Reported value | $631.6M |
| Positions | 38 |
| Change in reported value | +2.8% |
| New positions | 13 |
| Exited positions | 11 |
| Position turnover | 49.0% |
| Top-10 concentration | 39.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
38 | $753.0M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
31 | $934.7M |
|
Q1 2026 13F
Filed May 15, 2026
|
33 | $895.1M |
|
Q4 2025 13F
Filed Feb 13, 2026
|
33 | $875.2M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
29 | $666.0M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
35 | $536.0M |
|
Q1 2025 13F
Filed May 15, 2025
|
35 | $496.1M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
36 | $558.3M |
|
Q3 2024 13F
Filed Nov 7, 2024
|
38 | $631.6M |
|
Q2 2024 13F
Filed Aug 8, 2024
|
36 | $614.7M |
|
Q1 2024 13F
Filed May 6, 2024
|
34 | $668.5M |
|
Q4 2023 13F
Filed Feb 8, 2024
|
31 | $696.3M |
Top 20 holdings · Q3 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | NUVL NUVALENT INC | $36.7M | 5.82% |
| 2 | ARGX ARGENX SE | $29.5M | 4.67% |
| 3 | INSM INSMED INC | $26.0M | 4.12% |
| 4 | MIRM MIRUM PHARMACEUTICALS INC | $25.3M | 4.0% |
| 5 | PCVX VAXCYTE INC | $24.2M | 3.84% |
| 6 | AXSM AXSOME THERAPEUTICS INC | $22.9M | 3.63% |
| 7 | SNDX SYNDAX PHARMACEUTICALS INC | $22.9M | 3.62% |
| 8 | ASND ASCENDIS PHARMA A/S | $22.5M | 3.56% |
| 9 | NTRA NATERA INC | $19.8M | 3.13% |
| 10 | ITCI INTRA-CELLULAR THERAPIES INC | $18.6M | 2.95% |
| 11 | CRNX CRINETICS PHARMACEUTICALS IN | $18.1M | 2.86% |
| 12 | TMDX TRANSMEDICS GROUP INC | $17.9M | 2.84% |
| 13 | ACLX ARCELLX INC | $17.9M | 2.83% |
| 14 | BPMC BLUEPRINT MEDICINES CORP | $16.6M | 2.62% |
| 15 | VRNA VERONA PHARMA PLC | $16.5M | 2.61% |
| 16 | VRTX VERTEX PHARMACEUTICALS INC | $16.4M | 2.59% |
| 17 | BHVN BIOHAVEN LTD | $15.8M | 2.5% |
| 18 | ESTA ESTABLISHMENT LABS HLDGS INC | $15.4M | 2.45% |
| 19 | MRUS MERUS N V | $15.4M | 2.44% |
| 20 | ORIC ORIC PHARMACEUTICALS INC | $14.9M | 2.35% |
Values as reported on the Q3 2024 Form 13F. Every position is in the holdings table below.